Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.

Jaffe K, Slat S, Chen L, Macleod C, Bohnert A, Lagisetty P. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults. [Letter to the Editor]. Journal of substance use and addiction treatment. 2024 May 2; 209361.

INTRODUCTION: Medications for opioid use disorder (MOUD) including methadone (MMT), buprenorphine (BUP), and naltrexone (NTX) are safe and effective. However, there are significant negative perceptions surrounding MOUD, creating barriers to uptake. While research on MOUD stigma has largely focused on provider and patient experiences, fewer studies have explored MOUD perceptions among the general public. Given that MOUD stigma expressed by social ties surrounding individuals with OUD can influence treatment choices, we assessed MOUD perceptions among U.S. adults to determine how beliefs impacted treatment preference. We further explored how MOUD perceptions may be amplified among racialized groups with histories of experiencing drug-related discrimination. METHODS: The study collected survey data from a diverse sample of U.S. adults (n? = 1508) between October 2020 and January 2021. The survey measured knowledge of MOUD and non-medication treatments, relative agreement with common MOUD perceptions, and treatment preferences. Multinomial logistic regression analysis tested associations with treatment preference, stratified by race/ethnicity. RESULTS: Descriptive results indicated that across groups, many respondents (66.8?%) had knowledge of MOUD, but believed MOUD was a "substitute" for opioids and had some degree of concern about misuse. Multivariable results showed knowledge of non-medication treatments was positively associated with MOUD preference among White (MMT OR? = 3.16, 95?% CI? = 1.35-7.39; BUP OR? = 2.69, CI? = 1.11-6.47), Black (MMT OR? = 3.91, CI? = 1.58-9.69), and Latino/a (MMT OR? = 5.12, CI? = 1.99-13.2; BUP OR? = 3.85, CI? = 1.5-9.87; NTX OR? = 4.51, CI? = 1.44-14.06) respondents. Among White respondents, we identified positive associations between MOUD experience and buprenorphine preference (OR? = 4.33, CI? = 1.17-16.06); non-medication treatment experience and preference for buprenorphine (OR? = 2.86, CI? = 1.03-7.94) and naltrexone (OR? = 3.17, CI? = 1.08-9.28). Concerns around misuse of methadone were negatively associated with methadone preference among White (OR? = 0.65, CI? = 0.43-0.98) and Latino/a (OR? = 0.49, CI? = 0.34-0.7), and concerns around misuse of buprenorphine was negatively associated with preference for MOUD among White (MMT OR? = 0.62, CI? = 0.39-0.99; BUP OR? = 0.48, CI? = 0.3-0.77; NTX OR? = 0.6, CI? = 0.36-0.99) and Latino/a (BUP OR? = 0.59, CI? = 0.39-0.89) respondents. CONCLUSIONS: This analysis offers critical insights into treatment perceptions beyond the patient population, finding that negative beliefs around MOUD are common and negatively associated with preferences for medication-based treatment. These findings highlight implications for public support of evidence-based treatment and lay the groundwork for future interventions addressing public stigma toward MOUD.